Postpartum disorder

Postpartum disorder is the umbrella term for psychiatric illness that begins during pregnancy or in the weeks after delivery, covering postpartum depression, postpartum anxiety, postpartum obsessive-compulsive disorder, postpartum psychosis and puerperal adjustment disorder.

The umbrella matters practically because the component disorders differ enormously in urgency, from a self-limited mood lability that needs only reassurance to a psychosis that is a psychiatric and obstetric emergency.

Terminology and classification

• ICD-10 places puerperal mental disorders in the F53 block, with F53.0 for mild disorders associated with the puerperium, F53.1 for severe disorders, F53.8 for other specified forms and F53.9 for the unspecified category.
• ICD-10-CM adds O90.6 for postpartum mood disturbance, which sits in the obstetric chapter rather than the mental health chapter and is used when the puerperal context is the reason for the encounter.
• ICD-11 does not create a separate puerperal chapter, so the disorder is coded under its parent category such as 6A70 major depressive disorder while the postpartum context is recorded as a clinical descriptor.
• DSM-5 applies a peripartum onset specifier when symptoms begin during pregnancy or within four weeks of delivery, which is narrower than the six-week puerperium used by ICD-10.
• Ontology anchors include MONDO:0044014 for the umbrella concept, MeSH D050032 for postpartum depression, NCIT:C114389 and SNOMED CT 52772002, with Wikidata Q81923871 as the cross-reference hub.
• The umbrella excludes the baby blues, which affect up to 80 per cent of women in the first two weeks and resolve without treatment, and it excludes isolated postpartum physical disorders such as haemorrhage or sepsis.

History

• Puerperal insanity was described as a distinct clinical form in the nineteenth century, and asylum records show that childbirth-related psychosis accounted for a substantial share of female admissions.
• Twentieth-century obstetrics separated the benign baby blues from postpartum depression, and the two were no longer treated as points on a single continuum of puerperal madness.
• The Edinburgh Postnatal Depression Scale was published in 1987 by Cox, Holden and Sagovsky, and it replaced generic depression scales that were inflated by normal postpartum fatigue and mood lability.
• The DSM-IV introduced a postpartum onset specifier in 1994, and DSM-5 broadened it to peripartum onset in 2013 to capture depression that begins during pregnancy.
• Brexanolone became the first drug approved specifically for postpartum depression when the United States Food and Drug Administration licensed it in 2019, and oral zuranolone followed in 2023.
• The American College of Obstetricians and Gynecologists recommended routine screening in 2018 and the United States Preventive Services Task Force graded screening as a B recommendation in 2019, which moved detection into routine obstetric care.

Epidemiology

• Postpartum depression affects about 10 to 15 per cent of women in high-income settings, and the Centers for Disease Control and Prevention reported 13.2 per cent in its 2018 multistate surveillance, roughly one in eight mothers.
• Rates are higher in low and middle income countries and in populations exposed to intimate partner violence, food insecurity or conflict, where estimates reach 20 to 25 per cent.
• Postpartum anxiety is estimated at 10 to 15 per cent and frequently coexists with depression, so the two are better regarded as overlapping presentations than as separate epidemics.
• Postpartum psychosis occurs in roughly one to two per thousand births, and about 80 per cent of episodes begin within the first two weeks, often within the first seventy-two hours.
• The baby blues affect up to 80 per cent of women, peak on the third to fifth day and resolve by the end of the second week, so persistence beyond two weeks is the practical threshold for a disorder.
• Postpartum thyroiditis occurs in 5 to 10 per cent of women and produces a thyrotoxic phase at one to four months followed by hypothyroidism, which can mimic or aggravate postpartum depression.
• Risk factors include previous postpartum depression with a recurrence risk near 40 per cent, prior bipolar disorder, adolescent pregnancy, preterm or complicated delivery, lack of partner support and severe sleep deprivation.
• In the United Kingdom, suicide and overdose account for about one in five maternal deaths in the first year after birth, which is why perinatal mental illness is now treated as a core component of maternity safety.

Pathophysiology

• The abrupt withdrawal of oestrogen and progesterone after delivery, after months of placental steroid production, is the oldest and still the most plausible hormonal explanation for postpartum mood disorders.
• Oestradiol modulates serotonergic and dopaminergic transmission, and the speed of its fall rather than the absolute level may determine who develops symptoms, which would explain the link to abrupt delivery or surgical events.
• Postpartum psychosis is strongly associated with bipolar disorder, and a large proportion of first episodes prove to be the inaugural manifestation of bipolar illness rather than a separate disease.
• Sleep deprivation in the third trimester and the fragmented sleep of the newborn period disrupt circadian and hypothalamic-pituitary-adrenal regulation, and sleep loss is itself a documented trigger of manic and psychotic episodes.
• Inflammatory and neuroimmune changes of pregnancy resolve slowly after delivery, and persistent elevation of cytokines has been linked in cohort studies to postpartum depressive symptoms.
• Psychosocial mechanisms, including the shift in identity, the burden of infant care, loss of autonomy and inadequate partner support, interact with the biological changes rather than acting as an alternative explanation.

Clinical features

• Postpartum depression presents with persistent sadness, anhedonia, guilt, worthlessness, intrusive thoughts of harm, sleep disturbance beyond infant-driven waking and difficulty bonding with the baby.
• Postpartum anxiety presents with excessive worry about the infant, checking behaviours, restlessness, palpitations, panic attacks and a fear of being alone with the baby.
• Postpartum obsessive-compulsive disorder often centres on intrusive thoughts of contamination or of harming the infant, and the crucial clinical point is that such thoughts are distressing and resisted rather than endorsed.
• Postpartum psychosis presents with delusions, hallucinations, disorganised behaviour, confusion that fluctuates, and delusions specifically concerning the infant, and it may include suicidal or infanticidal intent.
• Severe cases carry risks of maternal suicide, infanticide, neglect and impaired mother-infant attachment, and these risks are the reason psychosis is managed as an emergency rather than in outpatient care.
• Even mild untreated depression has downstream effects on breastfeeding duration, infant bonding, partner relationship and child cognitive and emotional development, which is why subthreshold cases are still treated.

Diagnosis

• Screening should be universal rather than symptom-triggered, and the Edinburgh Postnatal Depression Scale is the most widely validated instrument with a threshold of 13 or above indicating probable depression.
• The scale deliberately omits physical symptoms such as sleep loss and weight change, because those are normal after childbirth and would otherwise inflate scores.
• Anxiety requires a separate instrument such as the GAD-7 or the Perinatal Anxiety Screening Scale, because the EPDS captures anxiety only partially and misses pure postpartum anxiety.
• Assessment must include direct questioning about intrusive thoughts, suicidal ideation and thoughts of harming the infant, since patients rarely volunteer these spontaneously.
• Laboratory evaluation should exclude thyroid dysfunction, anaemia and vitamin deficiency, and urinalysis and infection screening should be considered when physical symptoms are prominent.
• Any woman with suspected psychosis, mania or severe depression needs same-day psychiatric assessment with an explicit risk plan covering the infant as well as the mother.
• The differential includes the baby blues, adjustment disorder, major depressive disorder unrelated to childbirth, bipolar disorder, thyroid disease, sleep deprivation and, rarely, postpartum cardiomyopathy presenting with fatigue.

Management

• Mild to moderate depression is treated first with evidence-based psychotherapy, and cognitive behavioural therapy and interpersonal therapy both have trial support in the perinatal population.
• Selective serotonin reuptake inhibitors are the mainstay when medication is needed, and sertraline is usually preferred because its milk transfer is low and its safety data in lactation are the most extensive.
• Brexanolone, an intravenous neuroactive steroid, produces rapid improvement over a sixty-hour infusion, and oral zuranolone given for fourteen days offers a similar mechanism without admission.
• Postpartum psychosis requires inpatient psychiatric care, with antipsychotics, lithium where bipolar disorder is suspected, electroconvulsive therapy for refractory or life-threatening cases, and supervision of infant contact.
• Prophylaxis in a subsequent pregnancy is a major decision, and lithium started late in pregnancy or immediately postpartum reduces recurrence of postpartum psychosis substantially in women with bipolar disorder.
• Practical support is treatment, not an adjunct, because protected sleep, help with night feeds, childcare and partner involvement measurably reduce symptom severity.
• Breastfeeding should be supported rather than discouraged, since most antidepressants are compatible with lactation and cessation can worsen guilt and bonding difficulties.
• The prognosis is good with treatment, with most women recovering within six to twelve months, but recurrence in a later pregnancy is around one in three to one in two for depression and much higher for psychosis.

Research and controversies

• Whether universal screening actually improves outcomes, rather than merely increasing detection, remains contested, and trials have not consistently shown benefit on hard maternal or infant endpoints.
• The mechanism of the rapid effect of brexanolone and zuranolone is attributed to GABA-A receptor potentiation, but how that produces antidepressant action within days rather than weeks is still unexplained.
• Long-term child outcomes of untreated maternal depression are well documented, but whether treatment reverses the developmental risk has been addressed in very few prospective studies.
• The distinction between postpartum depression and depression that happens to occur postpartum is unresolved, and genetic and biomarker studies suggest that the two may not be biologically identical.
• Perinatal psychiatry now needs pragmatic trials in low-resource settings, task-shifting models and implementation research, because the treatments with the best evidence are the least available where the burden is greatest.